Azacitidine + Quizartinib combination
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-04-16 — Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations: Phase I/II trial (trial-early) evaluating azacitidine + quizartinib in MDS or MDS/MPN harboring FLT3 or CBL mutations, with co-primary objectives of safety, dose-finding (RP2D), and preliminary efficacy in this molecularly defined overlap-syndrome subgroup. (novelty: 3)
Open questions
Related
Contributing findings
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
16-apr-2026
novelty 3
per-area 3
introduces